Navigation Links
Many HIV Patients Carry Strain With Drug-Resistant Mutation
Date:2/28/2011

MONDAY, Feb. 28 (HealthDay News) -- A new study estimates that between 10 percent and 15 percent of HIV patients in Europe and the United States are infected with a form of HIV that already has at least one drug-resistant mutation.

The researchers found that the risk of treatment failure in these patients is three times higher than normal, and said their findings confirm the need for drug resistance testing in new patients to determine which antiretroviral drugs are most likely to be successful.

For the study, 10,056 HIV patients who were beginning combination antiretroviral therapy (cART) for the first time were categorized into three resistance categories: 90.5 percent (9,102 patients) had no transmitted drug-resistance (TDR); 4.7 percent (475 patients) had at least one mutation and were receiving fully active cART; 4.8 percent (479 patients) had at least one mutation and were resistant to at least one prescribed drug.

Compared to patients without TDR, those with TDR and resistance to at least one prescribed drug were more than three times as likely to experience treatment failure, confirming "the need for at least three fully active antiretroviral drugs to optimize the virological response to a first-line regimen," the researchers wrote.

But the risk of treatment failure was not significantly different between patients without TDR and those with TDR taking a fully active cART regimen containing drugs not compromised by resistance.

The researchers also found that treatment failure was higher among patients with TDR who were taking two nucleotide reverse transcriptase inhibitors (NRTIs) plus one non-nucleotide reverse transcriptase inhibitor (NNRTI) and were predicted to be on a fully active treatment, compared to patients on protease inhibitor-based regimens whose risk of treatment failure was similar to patients with no TDR.

"If drug-resistant mutations are detected before treatment initiation, a ritonavir-boosted protease inhibitor can be included in the first treatment regimen, which, because of its higher genetic barrier, could better protect from the risk of virological failure than could NNRTI," Dr. Linda Wittkop, of INSERM, University Bordeaux Segalen in Bordeaux, France, and colleagues wrote.

"These findings confirm present treatment guidelines for HIV, which state that the initial treatment choice should be based on resistance testing in treatment-naive patients," they concluded.

The study is published in the Feb. 28 online edition of The Lancet Infectious Diseases.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about HIV treatment.

-- Robert Preidt

SOURCE: The Lancet Infectious Diseases, news release, Feb. 27, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Doctors Can Influence Patients to Lose Weight: Studies
2. Heart Patients With Depression Often Find ER Delays
3. Experts call for greater pain assessment in hospitals as 65 percent of patients report problems
4. Fish Oil Seems to Help Cancer Patients Preserve Muscle
5. Standard Exams Might Not Catch Full Potential of Brain Damaged Patients
6. New way to identify patients at risk of dysphagia after head and neck cancer treatment
7. Type 1 Diabetes Patients Need New Kidney Therapies: Study
8. Many Dialysis Patients at Risk for High Radiation Exposure
9. Statins Might Help HIV Patients, Study Suggests
10. Most locked-in syndrome patients say they are happy
11. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many HIV Patients Carry Strain With Drug-Resistant Mutation
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, ... NET Foundation Summit from February 21 - 23 in Beaver Creek, CO. It was ... marks the Summit’s second year in Beaver Creek, hosting over 60 faculty members and ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon ... to families and business owners in the greater Fort Lauderdale metropolitan region, is ... , For more than 30 years, LifeNet 4 Families has provided a broad ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... ... February 17, 2017 , ... The Price Agency, ... families and entrepreneurs in the Birmingham area, is announcing an ongoing charity event ... with her medically challenged son, Anius. , Anius is medically complex with diagnoses ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets announced ... Pharma Inc. (Nasdaq: EPIX ). The report ... Kumar Raja , PhD. ESSA Pharmaceuticals is ... resistant prostate cancer (CRPC). Its lead compound EPI-506, is ... amino-terminal domain of the androgen receptor, thereby has potential ...
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
Breaking Medicine Technology: